Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Caulfield

Showing results (31-40 of 91) with videos related to

Pageof 10
Sort By:
Drugs|March 16, 2005
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trialPeter S Sever, Björn Dahlöf, Neil R Poulter, et al.
Lancet (London, England)|September 13, 2005
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trialBjörn Dahlöf, Peter S Sever, Neil R Poulter, et al.
Lancet (London, England)|September 13, 2005
Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA)Neil R Poulter, Hans Wedel, Björn Dahlöf, et al.
European Heart Journal|January 8, 2008
The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closurePeter S Sever, Neil R Poulter, Bjorn Dahlof, et al.
Human Molecular Genetics|May 13, 2005
Haplotypes of the WNK1 gene associate with blood pressure variation in a severely hypertensive population from the British Genetics of Hypertension studyStephen J Newhouse, Chris Wallace, Richard Dobson, et al.
Human Molecular Genetics|March 18, 2006
Two-dimensional genome-scan identifies novel epistatic loci for essential hypertensionJordana Tzenova Bell, Chris Wallace, Richard Dobson, et al.
Journal of the American Heart Association|November 20, 2017
Combination Therapy Is Superior to Sequential Monotherapy for the Initial Treatment of Hypertension: A Double-Blind Randomized Controlled TrialThomas M MacDonald, Bryan Williams, David J Webb, et al.
Journal of Molecular Medicine (Berlin, Germany)|July 24, 2008
The novel genetic variant predisposing to coronary artery disease in the region of the PSRC1 and CELSR2 genes on chromosome 1 associates with serum cholesterolNilesh J Samani, Peter S Braund, Jeanette Erdmann, et al.
Circulation|November 23, 2005
Association of WNK1 gene polymorphisms and haplotypes with ambulatory blood pressure in the general populationMartin D Tobin, Stuart M Raleigh, Stephen Newhouse, et al.
British Journal of Haematology|May 30, 2018
Clinical-grade validation of whole genome sequencing reveals robust detection of low-frequency variants and copy number alterations in CLLJenny Klintman, Katerina Barmpouti, Samantha J L Knight, et al.
Pageof 10

Showing results (31-40 of 91) with videos related to

Sort By:
Pageof 10
Drugs|March 16, 2005
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trialPeter S Sever, Björn Dahlöf, Neil R Poulter, et al.
Lancet (London, England)|September 13, 2005
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trialBjörn Dahlöf, Peter S Sever, Neil R Poulter, et al.
Lancet (London, England)|September 13, 2005
Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA)Neil R Poulter, Hans Wedel, Björn Dahlöf, et al.
European Heart Journal|January 8, 2008
The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closurePeter S Sever, Neil R Poulter, Bjorn Dahlof, et al.
Human Molecular Genetics|May 13, 2005
Haplotypes of the WNK1 gene associate with blood pressure variation in a severely hypertensive population from the British Genetics of Hypertension studyStephen J Newhouse, Chris Wallace, Richard Dobson, et al.
Human Molecular Genetics|March 18, 2006
Two-dimensional genome-scan identifies novel epistatic loci for essential hypertensionJordana Tzenova Bell, Chris Wallace, Richard Dobson, et al.
Journal of the American Heart Association|November 20, 2017
Combination Therapy Is Superior to Sequential Monotherapy for the Initial Treatment of Hypertension: A Double-Blind Randomized Controlled TrialThomas M MacDonald, Bryan Williams, David J Webb, et al.
Journal of Molecular Medicine (Berlin, Germany)|July 24, 2008
The novel genetic variant predisposing to coronary artery disease in the region of the PSRC1 and CELSR2 genes on chromosome 1 associates with serum cholesterolNilesh J Samani, Peter S Braund, Jeanette Erdmann, et al.
Circulation|November 23, 2005
Association of WNK1 gene polymorphisms and haplotypes with ambulatory blood pressure in the general populationMartin D Tobin, Stuart M Raleigh, Stephen Newhouse, et al.
British Journal of Haematology|May 30, 2018
Clinical-grade validation of whole genome sequencing reveals robust detection of low-frequency variants and copy number alterations in CLLJenny Klintman, Katerina Barmpouti, Samantha J L Knight, et al.
Pageof 10